Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Viracta Therapeutics's (Nanatinostat + Valganciclovir)?
(Nanatinostat + Valganciclovir) is a small molecule commercialized by Viracta Therapeutics, with a leading Phase II program in Natural Killer...
Data Insights
Risk adjusted net present value: What is the current valuation of Viracta Therapeutics's (Nanatinostat + Valganciclovir)?
(Nanatinostat + Valganciclovir) is a small molecule commercialized by Viracta Therapeutics, with a leading Phase II program in Natural Killer...